Möchten Sie immer auf dem neuesten Stand bleiben?

Ad hoc announcement pursuant to Art. 53 LR André C. Muller, current CEO of Idorsia, to retire and act as an advisor to the company to ensure a smooth transition Allschwil, Switzerland – June 10,...

Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025...

Allschwil, Switzerland – May 28, 2025At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the...

Ad hoc announcement pursuant to Art. 53 LR CHF 150 million new money facility from bondholders now implemented and providing cash runway to mid-2026Holistic convertible debt restructuring...

Allschwil, Switzerland – May 2, 2025Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 30, 2025Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2025. Business highlights Q1...

Daridorexant improved sleep maintenance throughout the entire night, including the last quarter, while also improving next-morning sleepiness.Daridorexant improved next-morning sleepiness compared to...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 16, 2025Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere...

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertension...

Allschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and...